CA2232682A1 - Use of prolactin as a tgf-beta antagonist - Google Patents

Use of prolactin as a tgf-beta antagonist Download PDF

Info

Publication number
CA2232682A1
CA2232682A1 CA002232682A CA2232682A CA2232682A1 CA 2232682 A1 CA2232682 A1 CA 2232682A1 CA 002232682 A CA002232682 A CA 002232682A CA 2232682 A CA2232682 A CA 2232682A CA 2232682 A1 CA2232682 A1 CA 2232682A1
Authority
CA
Canada
Prior art keywords
tgf
prolactin
cells
cell
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232682A
Other languages
English (en)
French (fr)
Inventor
Susan M. Richards
John M. Mcpherson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232682A1 publication Critical patent/CA2232682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002232682A 1996-04-30 1997-04-30 Use of prolactin as a tgf-beta antagonist Abandoned CA2232682A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1649296P 1996-04-30 1996-04-30
US60/016,492 1996-04-30

Publications (1)

Publication Number Publication Date
CA2232682A1 true CA2232682A1 (en) 1997-11-06

Family

ID=21777407

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232682A Abandoned CA2232682A1 (en) 1996-04-30 1997-04-30 Use of prolactin as a tgf-beta antagonist

Country Status (5)

Country Link
EP (1) EP0921809A4 (de)
JP (1) JP2000510112A (de)
AU (1) AU2749697A (de)
CA (1) CA2232682A1 (de)
WO (1) WO1997040848A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1998810A4 (de) 2006-03-13 2009-09-02 Univ Johns Hopkins Erhöhung der endothelialen thromboresistenz
HUE035575T2 (en) 2006-10-03 2018-05-28 Genzyme Corp Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia
PT3117709T (pt) 2010-03-12 2018-11-15 Genzyme Corp Terapêutica combinada para o tratamento do cancro da mama
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
US11382904B2 (en) 2013-10-31 2022-07-12 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021625A1 (en) * 1994-02-14 1995-08-17 Genzyme Corporation Prolactin as a vaccine adjuvant

Also Published As

Publication number Publication date
AU2749697A (en) 1997-11-19
EP0921809A4 (de) 2001-10-24
JP2000510112A (ja) 2000-08-08
WO1997040848A1 (en) 1997-11-06
EP0921809A1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
Simorre-Pinatel et al. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway.
Zhang et al. Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages
Cooper et al. Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta
US5612211A (en) Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
Libby et al. Production of platelet-derived growth factor–like mitogen by smooth-muscle cells from human atheroma
Gospodarowicz Growth factors and their action in vivo and in vitro
Limb et al. Cytokines in proliferative vitreoretinopathy
Roberts et al. The transforming growth factor-β s
Merwin et al. Transforming growth factor beta1 modulates extracellular matrix organization and cell‐cell junctional complex formation during in vitro angiogenesis
Righi et al. Monokine production by microglial cell clones
DE69914463T2 (de) Therapeutische chemokine rezeptor antagonisten
US7410639B2 (en) Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use
Dr. Weir et al. Macrophage colony‐stimulating factor release and receptor expression in bone cells
DE60103052T2 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
JP2006087434A (ja) 新規な神経栄養因子
Hou et al. Astrogliosis in culture. IV. Effects of basic fibroblast growth factor
JP2002539082A (ja) 血管内皮増殖因子２
PT946199E (pt) Células sensíveis a ftcβ1 derivadas de medula óssea
CA2232682A1 (en) Use of prolactin as a tgf-beta antagonist
US20050032697A1 (en) Heparin binding VEGFR-3 ligands
EP0437281B1 (de) Zubereitung enthaltend ein saures Fibroblastewachstumfaktor (aFGF)
US8420780B2 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
US20080214463A1 (en) Method for cell adhesion and wound healing
WO1991018620A1 (en) Stimulation of bone marrow stromal and progenitor cells
Clark et al. Transforming growth factor-β-like activity in tumors of the central nervous system

Legal Events

Date Code Title Description
FZDE Dead